Skip to main content

Table 1 Comparison of the baseline characteristics between the advanced and non-advanced idiopathic pulmonary fibrosis groups

From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Characteristic

Total

Advanced

Non-advanced

P-value

Number of patients

108

51

57

 

Age, years

66.7 ± 7.9

66.4 ± 8.6

68.2 ± 7.2

0.236

Male

86 (79.6)

39 (76.5)

47 (82.5)

0.441

Smoking status

   

0.027

 Never smoker

25 (23.1)

16 (31.4)

9 (15.8)

 

 Former smoker

79 (73.1)

35 (68.6)

44 (77.2)

 

 Current smoker

4 (3.7)

0 (0.0)

4 (7.0)

 

Body mass index, kg/m2

23.3 ± 3.2

22.7 ± 3.4

24.2 ± 2.7

0.018

Time since diagnosis, months

39.7 ± 32.0

41.2 ± 35.3

38.9 ± 29.1

0.709

Comorbidities

 Diabetes mellitus

22 (20.4)

9 (17.6)

13 (22.8)

0.506

 Cardiovascular disease

11 (10.2)

4 (7.8)

7 (12.3)

0.447

 Cerebrovascular disease

4 (3.7)

3 (5.9)

1 (1.8)

0.642

 Chronic liver disease

3 (2.8)

2 (3.9)

1 (1.8)

0.601

Pulmonary function test

 FVC, % predicted

56.2 ± 15.1

46.8 ± 9.5

65.3 ± 13.5

< 0.001

 DLco, % predicted

35.7 ± 12.6

27.1 ± 9.8

43.6 ± 9.4

< 0.001

 TLC, % predicted

58.0 ± 12.2

50.8 ± 7.6

65.0 ± 11.5

< 0.001

6MWT

 Distance, m

341.2 ± 122.5

275.0 ± 107.4

411.9 ± 96.4

< 0.001

 Lowest SaO2, %

84.2 ± 5.3

82.8 ± 4.8

87.4 ± 4.8

< 0.001

SPAP, mmHga

36.4 ± 1.1

38.8 ± 13.0

34.2 ± 9.2

0.039

Previous treatment

 Pirfenidone

20 (18.5)

10 (19.3)

10 (17.5)

0.783

 Prednisolone

17 (15.7)

13 (25.5)

4 (7.0)

0.008

 Immunosuppressants

11 (10.2)

9 (17.6)

2 (3.5)

0.015

N-Acetylcysteine

5 (4.6)

0 (0.0)

5 (8.8)

0.059

 None

66 (60.6)

26 (51.0)

40 (70.2)

0.041

  1. Data are presented as mean ± standard deviation or number (%), unless otherwise indicated
  2. FVC Forced vital capacity, DLco Diffusing capacity of the lung for carbon monoxide, TLC Total lung capacity, 6MWT 6 min walk test, SaO2 Saturation of oxygen, SPAP Estimated systolic pulmonary arterial pressure
  3. aMeasured by echocardiography